Northwest Biotherapeutics Inc NWBO

Healthcare Biotechnology

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

OTCQB:NWBO - Post by User

Northwest Biotherapeutics Inc

Bullboard Posts

Post by pericles1on Jan 13, 2015 11:03am

100 Views

Post# 23313383

New presentation

I was not impressed with the latest presentation. In September Linda said Phase II would start in the fall. Now she does not even give a indication when it will start and we are over three weeks into winter. Also she says they are speeding up the phase three with no information on how that's being done. It was a minor disappointment for me, their must be some complication on Direct for the timeline to be off that much! The timelines aways seem to be a moving target.

Bullboard Posts

Gold vs. bitcoin, where should you invest?